Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 16, 2020 21:00 ET | Source: Fior Markets

Global Diphtheria, Pertussis, and Tetanus (DTaP) Vaccine Market is Expected to Reach USD 5.07 Billion by 2026 : Fior Markets

New Jersey, NJ, Jan. 16, 2020 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, the global diphtheria, pertussis, and tetanus (DTaP) vaccine market is expected to grow from USD 2.97...
April 15, 2019 13:04 ET | Source: Reports And Data

Tetanus Toxoid Vaccine Market To Reach USD 6.46 Billion By 2026 | Reports And Data

The rise in the number of reported cases of tetanus and diphtheria in the developing countries will be the major factor influencing the market growth. Market Size – USD 4.35 Billion in 2018, Market...
April 15, 2019 12:14 ET | Source: Reports And Data

DTaP Vaccine Market To Reach USD 5.00 Billion By 2026 | Reports And Data

Growing demand for DTaP vaccines to prevent the occurrence of diseases such as diphtheria, tetanus, and pertussis is a significant factor expected to stimulate market growth. Market Size – USD 2.88...
July 05, 2017 09:00 ET | Source: ILiAD Biotechnologies, LLC

ILiAD Biotechnologies BPZE1 Pertussis Vaccine Reaches Key Milestones Including Positive Phase 1b Clinical Study Data

NEW YORK, July 05, 2017 (GLOBE NEWSWIRE) -- ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotechnology company, today announced promising results from its Phase 1b pertussis vaccine clinical...
April 03, 2017 16:00 ET | Source: Great Basin Scientific, Inc.

Great Basin Scientific Receives FDA 510(k) Clearance for Bordetella Direct Test

SALT LAKE CITY, April 03, 2017 (GLOBE NEWSWIRE) -- Great Basin Scientific, Inc. (OTCQB:GBSN), a molecular diagnostics company, has received U.S. Food & Drug Administration (FDA) clearance for...
February 01, 2017 07:00 ET | Source: Great Basin Scientific, Inc.

Great Basin Scientific Completes Clinical Trial, Submits FDA 510(k) Application for Bordetella Direct Test

SALT LAKE CITY, Feb. 01, 2017 (GLOBE NEWSWIRE) -- Great Basin Scientific, Inc. (OTCQB:GBSN), a molecular diagnostics company, today announced the completion of the clinical trial and 510(k)...
February 19, 2016 09:55 ET | Source: ILiAD Biotechnologies, LLC

Phase 1b Clinical Trial of BPZE1 Pertussis Vaccine Completes Enrollment of Randomized Study Groups

NEW YORK, Feb. 19, 2016 (GLOBE NEWSWIRE) -- ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotechnology company, announced today that enrollment has been completed for three randomized groups...